CBD and Epilepsy: The Strongest Evidence We Have

The One Indication That Cleared the Highest Bar

CBD is credited with a long list of benefits online, most of it built on small studies, animal models or personal accounts. Epilepsy is different. A purified CBD medicine has been through randomised, placebo-controlled trials and holds regulatory approval in the United States and Europe for three specific, severe childhood-onset epilepsies: Dravet syndrome, Lennox-Gastaut syndrome, and seizures associated with tuberous sclerosis complex.

That approval came in 2018, with tuberous sclerosis added in 2020. It was the first cannabis-derived prescription medicine approved in the United States, and it changed the conversation — not because it proved CBD works generally, but because it proved a specific preparation works for specific conditions at specific doses.

What the Trials Actually Showed

Across the pivotal studies, children receiving CBD alongside their existing anti-seizure medication had meaningfully fewer seizures than those receiving placebo. The effect was real and reproducible.

It is worth being precise about what that means. It was added to existing treatment, not a replacement. It reduced seizure frequency; it did not eliminate seizures for most participants. And the doses were far higher than anything sold over the counter — titrated by body weight, commonly reaching several hundred milligrams a day for a child.

Why the Dose Matters So Much

This is the part most CBD marketing skips. The epilepsy trials used doses starting around 2.5 mg per kilogram of body weight twice daily, increasing as tolerated. For a 30 kg child that begins near 150 mg a day and can go considerably higher.

A typical over-the-counter CBD product delivers 10 to 50 mg per dose. Citing the epilepsy evidence to support a 20 mg supplement is not a small exaggeration — it is a different order of magnitude. See our guide to CBD dosing for how that arithmetic works in practice.

Real Medicine Means Real Side Effects

CBD at therapeutic doses is not inert. The trials reported sleepiness, reduced appetite, diarrhoea, fatigue and — importantly — elevated liver enzymes, particularly in patients also taking valproate. Liver monitoring is part of the standard protocol.

There were also clear drug interactions. CBD raises blood levels of clobazam, a medication many of these patients already take, which accounts for some of the drowsiness and some of the benefit. That is exactly why this belongs under medical supervision rather than self-management.

What It Means for Everyone Else

The honest read is that epilepsy sets the standard, not the precedent. It demonstrates CBD can be a genuine pharmaceutical when it is purified, correctly dosed and properly monitored. It does not establish that CBD treats anxiety, pain or inflammation at the doses most people take — those questions have their own, thinner evidence, which we cover in what the evidence says by condition.

If you or your child has a treatment-resistant epilepsy, this is a conversation worth having with a physician who knows the material. If you are considering CBD for something else, the epilepsy data is encouraging about the compound and tells you very little about your situation.